CD40 and neoplasm: In leukemia, prostate, lung, pancreatic, colon, and gastric cancers, CXCL13 exhibits pro-cancer effects by recruiting B cells [86,87,115,116], CD68+ macrophages [18], regulatory B cells (Bregs) [117,118], Treg [119], and CD40+ MDSCs [120], shaping an immune-suppressive TME to trigger tumorigenesis and tumor progression (Figure 7A).